Dermatology

D. farinae and D. pteronyssinus positive skin prick test results were much more frequent in patients >18 years.

Ustekinumab should be prescribed cautiously to those at high cardiovascular risk.

Both antihistamines are indicated for treatment of chronic idiopathic urticaria, yet olopatadine demonstrates better clinical improvements and fewer adverse events.

Patients impacted by pruritus were more depressed and anxious than a comparison control group.

More studies are needed on the effectiveness and safety of plaque psoriasis therapies for older patients.

More trials must include older patients in order to better understand the safety and efficacy of systemic treatments for atopic dermatitis.

The study addresses safety concerns related to the risk of keratinocyte carcinoma for patients with atopic dermatitis.

Older, white patients and those who use linagliptin are at a higher risk of bullous pemphigoid.

The FDA will be working over the next few months to ensure tralokinumab is efficient for atopic dermatitis.

An expert explains differences between tralokinumab and other popular agents for atopic dermatitis.

The expansion makes history for the injection biologic.

Kim Kjøller, MD, breaks down the findings from ECZTRA1, 2, and 3.

Kim Kjøller, MD, discusses how tralokinumab can be used for the treatment of atopic dermatitis.

Of the 21 patients included in the study with COVID-19 and skin rash, 29% had enanthem.

Although a majority of pediatricians are aware of the guidelines, less than one-third of survey respondents report full implementation.

The FDA is looking for more information regarding aspects of the chemistry, manufacturing, and controls process for the drug-device combination

Subcutaneous injections of nemolizumab in addition to topical agents result in a greater reduction in pruritus than placebo plus topical agents.

Patients with acne who receive isotretinoin treatment can expect a four- to five-fold improvement from baseline to follow-up in quality of life.

The FDA is allowing the pen to be used for the treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis (CRSwNP) patients at least 12 years old.

A dermatologist and clinical associate professor of dermatology discusses implementing telehealth in dermatology practices.

Currently, the use of minocycline is limited orally due to some systemic side effects.

The newest indication for the add-on biologic grants it use in children aged 6-11 years old with moderate to severe, uncontrolled atopic dermatitis.

Since the beginning of the COVID-19 pandemic most non-urgent medical appointments have been conducted using telehealth.

With the majority of the scientific research community focused, a COVID-19 vaccine could be on the horizon.

While recent data regarding remdesivir has been positive, there is still a need for medications in pill form to treat COVID-19 infections.